© 1997 by Oxford University Press
Journal Of The National Cancer Institute, Vol 89, 1498-1504, Copyright © 1997 by Oxford University Press
AC Ferrari, NN Stone, JN Eyler, M Gao, J Mandeli, P Unger, RE Gallagher and R Stock
BACKGROUND: Pathologic evidence of pelvic lymph node involvement is
obtained in 12%-20% of patients with localized prostate cancer that
exhibits high-risk features (defined on the basis of tumor size, serum
prostate-specific antigen [PSA] level, or Gleason score). The rate of
systemic failure (i.e., relapse) in patients with this type of prostate
cancer and no pathologic evidence of regional lymph node involvement is
55%-92% within 5 years of definitive local therapy. Since reverse
transcription-polymerase chain reaction (RT-PCR) methods are likely to be
more sensitive than routine pathologic examination in detecting metastatic
tumor cells, we compared the ability of the two approaches to detect
prostate cells in the pelvic lymph nodes of patients with localized,
high-risk disease. METHODS: Fifty-eight lymph node specimens isolated from
33 patients before definitive local therapy were examined. Expression of
PSA and prostate-specific membrane antigen (PSM) messenger RNAs in the
specimens was assessed by means of nested RT-PCR. RESULTS: Pathologic
examination identified tumor cells in the lymph nodes of four (12%) of the
33 patients, and PSA and/ or PSM expression was positive in specimens from
27 (82%) of the patients (two- sided P<.0001). The four patients with
positive pathologic findings also had positive RT-PCR results. Among the 29
patients with no pathologic evidence of lymph node involvement, 23 (79%)
tested positive by means of RT-PCR. In these 23 patients, PSM expression
was detected more frequently than PSA expression; however, in two patients,
only PSA expression was detected. CONCLUSIONS: Expression of
prostate-specific markers in the pelvic lymph nodes of patients with
localized, high-risk prostate cancer may indicate the presence of
metastatic tumor cells. Such cells may be responsible for the high rate of
systemic failure seen in these patients. Additional studies are required to
determine the prognostic relevance of our findings.
ARTICLES
Prospective analysis of prostate-specific markers in pelvic lymph nodes of patients with high-risk prostate cancer
Division of Neoplastic Diseases, Mount Sinai School of Medicine, New York, NY 10029, USA.
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  H. Miyake, I. Hara, T. Kurahashi, T.-a. Inoue, H. Eto, and M. Fujisawa Quantitative Detection of Micrometastases in Pelvic Lymph Nodes in Patients with Clinically Localized Prostate Cancer by Real-time Reverse Transcriptase-PCR Clin. Cancer Res., February 15, 2007; 13(4): 1192 - 1197. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. C. Ferrari, N. N. Stone, R. Kurek, E. Mulligan, R. McGregor, R. Stock, P. Unger, U. Tunn, A. Kaisary, M. Droller, et al. Molecular Load of Pathologically Occult Metastases in Pelvic Lymph Nodes Is an Independent Prognostic Marker of Biochemical Failure After Localized Prostate Cancer Treatment J. Clin. Oncol., July 1, 2006; 24(19): 3081 - 3088. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. L. Speight and M. Roach III Radiotherapy in the Management of Clinically Localized Prostate Cancer: Evolving Standards, Consensus, Controversies and New Directions J. Clin. Oncol., November 10, 2005; 23(32): 8176 - 8185. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. Kurek, G. Nunez, N. Tselis, L. Konrad, T. Martin, S. Roeddiger, G. Aumuller, N. Zamboglou, D. W. Lin, U. W. Tunn, et al. Prognostic Value of Combined "Triple"-Reverse Transcription-PCR Analysis for Prostate-Specific Antigen, Human Kallikrein 2, and Prostate-Specific Membrane Antigen mRNA in Peripheral Blood and Lymph Nodes of Prostate Cancer Patients Clin. Cancer Res., September 1, 2004; 10(17): 5808 - 5814. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. F. Shariat, M. P. Roudier, G. E. Wilcox, M. W. Kattan, P. T. Scardino, R. L. Vessella, S. Erdamar, C. Nguyen, T. M. Wheeler, and K. M. Slawin Comparison of Immunohistochemistry with Reverse Transcription-PCR for the Detection of Micrometastatic Prostate Cancer in Lymph Nodes Cancer Res., August 1, 2003; 63(15): 4662 - 4670. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C.-L. Gao, S. K. Rawal, L. Sun, A. Ali, R. R. Connelly, L. L. Banez, I. A. Sesterhenn, D. G. Mcleod, J. W. Moul, and S. Srivastava Diagnostic Potential of Prostate-specific Antigen Expressing Epithelial Cells in Blood of Prostate Cancer Patients Clin. Cancer Res., July 1, 2003; 9(7): 2545 - 2550. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Roach III, M. DeSilvio, C. Lawton, V. Uhl, M. Machtay, M.J. Seider, M. Rotman, C. Jones, S.O. Asbell, R.K. Valicenti, et al. Phase III Trial Comparing Whole-Pelvic Versus Prostate-Only Radiotherapy and Neoadjuvant Versus Adjuvant Combined Androgen Suppression: Radiation Therapy Oncology Group 9413 J. Clin. Oncol., May 15, 2003; 21(10): 1904 - 1911. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. F. Shariat, M. W. Kattan, S. Erdamar, C. Nguyen, P. T. Scardino, D. M. Spencer, T. M. Wheeler, and K. M. Slawin Detection of Clinically Significant, Occult Prostate Cancer Metastases in Lymph Nodes Using a Splice Variant-Specific RT-PCR Assay for Human Glandular Kallikrein J. Clin. Oncol., April 1, 2003; 21(7): 1223 - 1231. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Sanchez-Cespedes, M. Esteller, K. Hibi, F. O. Cope, W. H. Westra, S. Piantadosi, J. G. Herman, J. Jen, and D. Sidransky Molecular Detection of Neoplastic Cells in Lymph Nodes of Metastatic Colorectal Cancer Patients Predicts Recurrence Clin. Cancer Res., September 1, 1999; 5(9): 2450 - 2454. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. Pantel, R. J. Cote, and O. Fodstad Detection and Clinical Importance of Micrometastatic Disease J Natl Cancer Inst, July 7, 1999; 91(13): 1113 - 1124. [Abstract] [Full Text] [PDF]
|
|